KINIKSA PHARMACEUTICALS INTE (KNSA) Stock Fundamental Analysis
USA - NASDAQ:KNSA - GB00BRXB0C07 - Common Stock
38.86 USD
+0.97 (+2.56%)
38.86 USD
0 (0%)
Taking everything into account, KNSA scores 6 out of 10 in our fundamental rating. KNSA was compared to 536 industry peers in the Biotechnology industry. KNSA is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. KNSA is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings would make KNSA suitable for growth investing!
1. Profitability
1.1 Basic Checks
KNSA had positive earnings in the past year.
In the past year KNSA had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: KNSA reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: KNSA reported negative operating cash flow in multiple years.
1.2 Ratios
KNSA has a better Return On Assets (0.72%) than 89.93% of its industry peers.
The Return On Equity of KNSA (0.97%) is better than 91.04% of its industry peers.
The Return On Invested Capital of KNSA (0.65%) is better than 90.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.72% | ||
| ROE | 0.97% | ||
| ROIC | 0.65% |
ROA(3y)11.71%
ROA(5y)-15.78%
ROE(3y)13.22%
ROE(5y)-19.49%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
KNSA has a Profit Margin of 0.90%. This is amongst the best in the industry. KNSA outperforms 90.30% of its industry peers.
KNSA's Operating Margin of 0.85% is amongst the best of the industry. KNSA outperforms 90.30% of its industry peers.
With an excellent Gross Margin value of 85.93%, KNSA belongs to the best of the industry, outperforming 88.62% of the companies in the same industry.
KNSA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.85% | ||
| PM (TTM) | 0.9% | ||
| GM | 85.93% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.87%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so KNSA is destroying value.
Compared to 1 year ago, KNSA has more shares outstanding
The number of shares outstanding for KNSA has been increased compared to 5 years ago.
KNSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 10.47 indicates that KNSA is not in any danger for bankruptcy at the moment.
KNSA has a Altman-Z score of 10.47. This is amongst the best in the industry. KNSA outperforms 83.77% of its industry peers.
There is no outstanding debt for KNSA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 10.47 |
ROIC/WACC0.07
WACC9.28%
2.3 Liquidity
KNSA has a Current Ratio of 3.57. This indicates that KNSA is financially healthy and has no problem in meeting its short term obligations.
KNSA has a Current ratio (3.57) which is comparable to the rest of the industry.
KNSA has a Quick Ratio of 3.16. This indicates that KNSA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.16, KNSA is in line with its industry, outperforming 40.11% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.57 | ||
| Quick Ratio | 3.16 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 125.00% over the past year.
Looking at the last year, KNSA shows a very strong growth in Revenue. The Revenue has grown by 56.18%.
The Revenue has been growing by 122.27% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)125%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%483.33%
Revenue 1Y (TTM)56.18%
Revenue growth 3Y122.27%
Revenue growth 5YN/A
Sales Q2Q%51.65%
3.2 Future
The Earnings Per Share is expected to grow by 49.30% on average over the next years. This is a very strong growth
KNSA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.64% yearly.
EPS Next Y170.9%
EPS Next 2Y117.61%
EPS Next 3Y79.57%
EPS Next 5Y49.3%
Revenue Next Year34.22%
Revenue Next 2Y36.28%
Revenue Next 3Y29.21%
Revenue Next 5Y23.64%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
KNSA is valuated quite expensively with a Price/Earnings ratio of 971.50.
KNSA's Price/Earnings ratio is rather cheap when compared to the industry. KNSA is cheaper than 89.93% of the companies in the same industry.
KNSA is valuated expensively when we compare the Price/Earnings ratio to 27.49, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 23.29, which indicates a rather expensive current valuation of KNSA.
KNSA's Price/Forward Earnings ratio is rather cheap when compared to the industry. KNSA is cheaper than 92.16% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.99, KNSA is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 971.5 | ||
| Fwd PE | 23.29 |
4.2 Price Multiples
89.18% of the companies in the same industry are more expensive than KNSA, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, KNSA is valued cheaply inside the industry as 92.91% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 43.31 | ||
| EV/EBITDA | 398.95 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of KNSA may justify a higher PE ratio.
A more expensive valuation may be justified as KNSA's earnings are expected to grow with 79.57% in the coming years.
PEG (NY)5.68
PEG (5Y)N/A
EPS Next 2Y117.61%
EPS Next 3Y79.57%
5. Dividend
5.1 Amount
KNSA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
38.86
+0.97 (+2.56%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners93%
Inst Owner Change0%
Ins Owners3.79%
Ins Owner Change-2.02%
Market Cap2.88B
Analysts86.67
Price Target46.31 (19.17%)
Short Float %5.82%
Short Ratio4.59
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)141.63%
Min EPS beat(2)23.78%
Max EPS beat(2)259.48%
EPS beat(4)2
Avg EPS beat(4)-1537.64%
Min EPS beat(4)-5782.35%
Max EPS beat(4)259.48%
EPS beat(8)4
Avg EPS beat(8)-731.38%
EPS beat(12)8
Avg EPS beat(12)-432.45%
EPS beat(16)11
Avg EPS beat(16)-320.68%
Revenue beat(2)2
Avg Revenue beat(2)4.5%
Min Revenue beat(2)4.01%
Max Revenue beat(2)4.99%
Revenue beat(4)2
Avg Revenue beat(4)1.26%
Min Revenue beat(4)-2.63%
Max Revenue beat(4)4.99%
Revenue beat(8)5
Avg Revenue beat(8)3.77%
Revenue beat(12)9
Avg Revenue beat(12)8.7%
Revenue beat(16)11
Avg Revenue beat(16)8.8%
PT rev (1m)1.34%
PT rev (3m)25.41%
EPS NQ rev (1m)0%
EPS NQ rev (3m)72.3%
EPS NY rev (1m)0%
EPS NY rev (3m)-41.52%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.7%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 971.5 | ||
| Fwd PE | 23.29 | ||
| P/S | 5.44 | ||
| P/FCF | 43.31 | ||
| P/OCF | 43.02 | ||
| P/B | 5.82 | ||
| P/tB | 6.01 | ||
| EV/EBITDA | 398.95 |
EPS(TTM)0.04
EY0.1%
EPS(NY)1.67
Fwd EY4.29%
FCF(TTM)0.9
FCFY2.31%
OCF(TTM)0.9
OCFY2.32%
SpS7.14
BVpS6.68
TBVpS6.47
PEG (NY)5.68
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.72% | ||
| ROE | 0.97% | ||
| ROCE | 0.82% | ||
| ROIC | 0.65% | ||
| ROICexc | 1.5% | ||
| ROICexgc | 1.61% | ||
| OM | 0.85% | ||
| PM (TTM) | 0.9% | ||
| GM | 85.93% | ||
| FCFM | 12.56% |
ROA(3y)11.71%
ROA(5y)-15.78%
ROE(3y)13.22%
ROE(5y)-19.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.87%
GM growth 5YN/A
F-Score6
Asset Turnover0.8
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 30.43% | ||
| Cap/Sales | 0.09% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 1120.09% | ||
| Profit Quality | 1388.12% | ||
| Current Ratio | 3.57 | ||
| Quick Ratio | 3.16 | ||
| Altman-Z | 10.47 |
F-Score6
WACC9.28%
ROIC/WACC0.07
Cap/Depr(3y)8.83%
Cap/Depr(5y)180.67%
Cap/Sales(3y)0.05%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)125%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%483.33%
EPS Next Y170.9%
EPS Next 2Y117.61%
EPS Next 3Y79.57%
EPS Next 5Y49.3%
Revenue 1Y (TTM)56.18%
Revenue growth 3Y122.27%
Revenue growth 5YN/A
Sales Q2Q%51.65%
Revenue Next Year34.22%
Revenue Next 2Y36.28%
Revenue Next 3Y29.21%
Revenue Next 5Y23.64%
EBIT growth 1Y116.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year202.02%
EBIT Next 3Y106.77%
EBIT Next 5YN/A
FCF growth 1Y56.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y57.64%
OCF growth 3YN/A
OCF growth 5YN/A